EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitScoping Review

In vivo biomarkers for limbic-predominant age-related TDP-43 encephalopathy neuropathologic change (LATE-NC): A scoping review of proposed measures

Ravi Singh iD, Soala Reuben iD, Mathew Oyelami iD, Adesola Adeleye iD, Ewarld Marshall iD

Journal of Alzheimer’s Disease · 12.11.2026

DOI: 10.1177/13872877261505301 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Alzheimer’s Disease, online erschienen am 12.11.2026. Verfasst von Ravi Singh und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, St George's University, St George's, Grenada, West Indies. Die Arbeit nennt 89 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Limbic-predominant age-related TDP-43 encephalopathy neuropathologic change (LATE-NC) is a common cause of late-life amnestic dementia that mimics Alzheimer's disease but lacks a validated in vivo biomarker.

Objective

The authors sought to map the in vivo biomarker candidates for LATE-NC, characterize the type and quality of evidence for each, highlight their validation against postmortem TDP-43 staging and map their performance in both pure LATE-NC and mixed pathology.

Methods

Five databases were searched (PubMed/MEDLINE, EMBASE, Web of Science, Cochrane Library, Scopus). Eligible studies investigated in vivo biomarkers for LATE-NC in adults with mean age above 65. Two reviewers independently screened all records; a third adjudicated disagreements. Data were extracted across 24 fields and synthesized narratively.

Results

43 studies covering structural MRI (19), FDG-PET (8), plasma (7), diffusion MRI (4), multimodal MRI (1), CSF (2), TDP-43 PET (1), and linguistic markers (1) were reviewed. The most replicated signal was medial temporal lobe atrophy and hypometabolism. Several studies framed their candidate as a diagnostic validation against autopsy; yet only three reported formal performance metrics with stated cut-off values. A handful of studies (12%) tested in an independent cohort and the corpus contains only one study from outside North America and Europe (Japan).

Conclusions

Imaging evidence is well-anchored but mostly exploratory or surrogate validated at this stage. Plasma TDP-43 elevation is consistent but no commercial assay has a validated cut-point. Clinical translation requires external validation, cut-point-anchored diagnostic accuracy, and cohort diversification.

Schlagwörter

Stichwörter der Autor:innen

Alzheimer's diseaseTDP-43 proteinbiomarkershippocampal sclerosislimbic-predominant age-related TDP-43 encephalopathymagnetic resonance imagingneuropathologypositron emission tomographyscoping review

Autor:innen und Institutionen

  • Department of Pathology, St George's University, St George's, Grenada, West Indies.

ORCID-Profile: Ravi Singh, Soala Reuben, Mathew Oyelami, Adesola Adeleye, Ewarld Marshall

Zitieren

APA

Singh, R., Reuben, S., Oyelami, M., Adeleye, A., & Marshall, E. (2026). In vivo biomarkers for limbic-predominant age-related TDP-43 encephalopathy neuropathologic change (LATE-NC): A scoping review of proposed measures. Journal of Alzheimer’s Disease. https://doi.org/10.1177/13872877261505301

Vancouver

Singh R, Reuben S, Oyelami M, Adeleye A, Marshall E. In vivo biomarkers for limbic-predominant age-related TDP-43 encephalopathy neuropathologic change (LATE-NC): A scoping review of proposed measures. Journal of Alzheimer’s Disease. 2026. doi:10.1177/13872877261505301

BibTeX
@article{Singh2026,
  author = {Singh, Ravi and Reuben, Soala and Oyelami, Mathew and Adeleye, Adesola and Marshall, Ewarld},
  title = {In vivo biomarkers for limbic-predominant age-related TDP-43 encephalopathy neuropathologic change (LATE-NC): A scoping review of proposed measures},
  journal = {Journal of Alzheimer’s Disease},
  year = {2026},
  doi = {10.1177/13872877261505301}
}
Kostenlos starten →